Compare IONQ Inc (IONQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Merck & Co., Inc. — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 22× IONQ Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Merck & Co., Inc. for 98 Days on average.
| IONQ | MRK | |
|---|---|---|
Market Cap | $15.98B | $351.28B |
Volume | 22,848,240 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $82.09 | $156.43 |
52-Week Low | $26.59 | $82.49 |
Typical Hold Time | 33 Days | 98 Days |
Enterprise Value | $13.92B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.45, down 4.57% today, with bearish technical signals from moving averages but bullish oscillators. The company shows strong revenue growth ($130M in 2025 to $246M projected for 2026) but significant losses (-$510M net income in 2025). Recent Q2 2026 earnings missed expectations, while Q1 and Q4 2025 beat. Analyst consensus is split 50/50 buy/hold with a $62.75 price target, suggesting 59% upside potential from current levels.
IONQ presents high-risk, high-reward potential with substantial revenue growth offset by deep losses and negative margins. The quantum computing sector offers long-term upside if commercialization succeeds, but investors face dilution risk from continued cash burn and execution challenges in scaling technology. Current valuation multiples (P/S 54.74) appear stretched relative to profitability metrics.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
